Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial by Hess, V. et al.
Annals of Oncology 21: 2390–2395, 2010
doi:10.1093/annonc/mdq242
Published online 5 May 2010
original article
Combining gemcitabine, oxaliplatin and capecitabine
(GEMOXEL) for patients with advanced pancreatic
carcinoma (APC): a phase I/II trial
V. Hess1*, S. Pratsch1, S. Potthast2, L. Lee1, R. Winterhalder3, L. Widmer4, C. Cescato5,
A. Lohri6, L. Jost7, P. Stillhart1, B. Pestalozzi8 & R. Herrmann1
Departments of 1Medical Oncology; 2Radiology, University Hospital Basel; 3Department of Medical Oncology, Cantonal Hospital Lucerne; 4Onkozentrum Hirslanden,
Zurich; 5Department of Medical Oncology, St Clara Hospital Basel; 6Department of Medical Oncology, Cantonal Hospital Liestal; 7Department of Medical Oncology,
Cantonal Hospital Bruderholz; 8Department of Medical Oncology, University Hospital Zurich, Switzerland
Received 11 March 2010; revised 25 March 2010; accepted 25 March 2010
Background: Gemcitabine remains the mainstay of palliative treatment of advanced pancreatic carcinoma (APC).
Adding capecitabine or a platinum derivative each significantly prolonged survival in recent meta-analyses. The
purpose of this study was to determine dose, safety and preliminary efficacy of a first-line regimen combining all three
classes of active cytotoxic drugs in APC.
Patients and methods: Chemotherapy-naive patients with locally advanced or metastatic, histologically proven
adenocarcinoma of the pancreas were treated with a 21-day regimen of gemcitabine [1000 mg/m2 day (d) 1, d8],
escalating doses of oxaliplatin (80–130 mg/m2 d1) and capecitabine (650–800 mg/m2 b.i.d. d1–d14). The
recommended dose (RD), determined in the phase I part of the study by interpatient dose escalation in cohorts of
three to six patients, was further studied in a two-stage phase II part with the primary end point of response rate by
RECIST criteria.
Results: Forty-five patients were treated with a total of 203 treatment cycles. Thrombocytopenia and diarrhea were
the toxic effects limiting the dose to an RD of gemcitabine 1000 mg/m2 d1, d8; oxaliplatin 130 mg/m2 d1 and
capecitabine 650 mg/m2 b.i.d. d1–14. Central independent radiological review showed partial remissions in 41% [95%
confidence interval (CI) 26% to 56%] of patients and disease stabilization in 37% (95% CI 22% to 52%) of patients.
Conclusion: This triple combination is feasible and, by far, met the predefined efficacy criteria warranting further
investigations.
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introduction
Gemcitabine remains the mainstay of medical treatment of
advanced pancreatic carcinoma (APC), a disease with
increasing incidence [1]. Disappointingly, results of the vast
majority of large clinical trials studying gemcitabine-based
combinations—including combinations with novel targeted
drugs—did not meet expectations and survival for patients with
APC remains short with a median survival time between 4 and
8 months [2, 3].
Yet, small but important progress has been made. For the
first time since Burris’ pivotal trial in 1997 [4], a significant
survival gain for gemcitabine-based chemotherapy
combinations as compared with gemcitabine monotherapy was
shown in two meta-analyses. The combination of gemcitabine
with either of two classes of cytotoxic drugs—capecitabine [5]
or a platinum derivative [6]—each resulted in lengthened
overall survival.
Adding capecitabine, an oral fluoropyrimidine, to standard
gemcitabine reduced the hazard of death by 14% [hazard ratio
(HR) 0.86, 95% confidence interval (CI) 0.75–0.98, P = 0.02] in
a pooled analysis of 935 patients from three randomized
controlled trials (RCTs) [5, 7, 8]. The increase in toxicity for
the doublet was manageable consisting mainly of neutropenia
(not febrile) and hand–foot syndrome (HFS). Quality of life
during chemotherapy—a secondary end point in the two larger
RCTs [5, 7]—did not deteriorate in the combination arm [9].
Similarly, adding the platinum-derivative oxaliplatin to
gemcitabine led to an increase in objective response rate (RR;
17.3% versus 26.8%, P = 0.04) and progression-free survival
(3.7 versus 5.8 months, P = 0.04) but not to a significantly
lengthened survival in any single RCT [10, 11]. However, in
a large meta-analysis of 15 RCTs including 4465 patients, the
hazard of death was reduced by 15% (HR 0.85, 95% CI
0.76–0.96, P = 0.01) for all platinum-based gemcitabine
combinations [6]. Of note, clinical benefit ratio (CBR)
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significantly improved by adding oxaliplatin to gemcitabine
from 26.9% to 38.2% (P = 0.03) [10]. Gain in CBR was one of
the hallmarks of gemcitabine monotherapy when introduced as
a standard treatment in 1997 [4].
This prospective, multicenter phase I/II trial examines dose,
safety and preliminary efficacy of a triple combination of the
three most active cytotoxic drugs in APC—gemcitabine,
oxaliplatin and capecitabine (GEMOXEL).
patients and methods
patients
Chemotherapy-naive patients with histologically confirmed diagnosis of
locally advanced inoperable and/or metastatic adenocarcinoma of the pancreas
were eligible. Further inclusion criteria comprised a Karnofsky performance
status (KPS) of at least 60%, either measurable disease on computed
tomography (CT) scan or serum tumor marker CA 19-9 concentration
>1.5· the upper limit of laboratory normal (ULN) and age >18 years.
Patients were not eligible if they had received any prior chemotherapy for
pancreatic cancer (including adjuvant chemotherapy). Prior adjuvant
radiotherapy or concomitant radio-chemotherapy for pancreatic cancer was
allowed if it was completed >12 months before study inclusion. Other
exclusion criteria included known central nervous system metastases at the
time of enrollment, clinically significant cardiac disease (New York Heart
Association Class III–IV) or myocardial infarction within the previous 12
months, neurological disease with dys/paresthesia >grade 1 according to
National Cancer Institute—Common Toxicity Criteria (NCI–CTC), any
serious concomitant disorder incompatible with trial participation (in the
judgment of the investigator) or a psychiatric disability thought to be
clinically significant in the opinion of the investigator precluding informed
consent or interfering with compliance. Laboratory values that precluded
trial participation were absolute neutrophil count £1.5 · 109/l, platelet
count £100 · 109/l, hemoglobin £100 g/l, serum creatinine >1.25 · ULN,
aspartate aminotransferase, alanine aminotransferase and alkaline
phosphatase >2.5 or >5 ULN in the presence of liver metastases and
bilirubin >1.5 ULN (after treatment of obstructive jaundice, e.g. stent).
Written informed consent was obtained from each patient.
treatment
Treatment consisted of six cycles of a 3-week regimen of gemcitabine
(Gemzar, Eli Lilly, Vernier, Switzerland) given at fixed doses of 1000 mg/
m2 i.v. over 30 min on d1 and d8, oxaliplatin (Eloxatin, Sanofi Aventis,
Meyrin, Switzerland) given in escalating doses i.v. over 120 min on d1 and
capecitabine (Xeloda, Roche, Pharma, Remach, Switzerland) given orally
twice daily for 28 doses d1 through d14. After completing six cycles,
treatment with this regimen was continued in responding patients at the
discretion of the investigator. Dose was escalated in cohorts of three to six
patients according to the following scheme:
If one of three patients experienced dose-limiting toxicity (DLT) during
the first two cycles, three more patients were included at the same dose
level. If two or more patients experienced DLT, the previous dose level was
considered the recommended dose (RD) and all patients of the phase II part
of the study were treated at the RD.
DLTs were defined as any of the following: grade 4 neutropenia lasting
‡7 days or febrile neutropenia; grade 4 thrombocytopenia and grade 3/4
gastrointestinal symptoms (diarrhea, vomiting or mucositis), which were
not reduced to grade 1 within 2 days of appropriate supportive care; grade
3/4 skin toxicity, e.g. palmo-plantar erythrodysesthesia (HFS); grade 3/4
neurological toxicity, e.g. cold paresthesia, which did not resolve to grade 1
within 3 days after chemotherapy and any grade 3/4 toxicity, which was
considered to be dose limiting by the investigators.
Dose modifications for toxicity for each of the drugs were prespecified in
the protocol. After the occurrence of a grade 3 hematologic toxicity,
treatment was interrupted until the toxicity resolved to grade 0–1 and then
reinstalled at the same doses. After the occurrence of a grade 4 hematologic
toxicity or a grade 3 non-hematologic toxicity, treatment was interrupted
until resolution to grade 0–1 and then reintroduced at 75% of the doses of
gemcitabine and capecitabine and at the next lower dose level of oxaliplatin.
Treatment was discontinued after the occurrence of a grade 4 non-
hematologic toxicity. Toxic effects clearly attributable to a specific drug
(HFS to capecitabine; neuropathy to oxaliplatin) led to protocol-defined
reductions of the causative drug only.
Response assessment by CT scan was done at baseline, every 6 weeks
during active treatment and every 3 months during follow-up. An
experienced radiologist (SP)—blinded to the clinical history—reviewed CT
scans centrally and assessed the RR according to RECIST I criteria.
study design and statistics
This multicenter open-label phase I/II trial consisted of two parts: the phase
I part was designed according to a modified Fibonacci design with
interpatient dose escalation in cohorts of three to six patients with the
primary end point of protocol-defined DLT.
The phase II part was designed in two stages (Simon two-stage optimal
design) with an early stopping rule for safety: if one or fewer objective
responses were to be observed with the first 13 patients treated at the RD,
the trial was to be halted. Otherwise, 15 more patients were to be treated at
the RD, for a total of 28 patients at the RD. Given that the ‘true’ response
probability was 7.5%, there was a 74.55% probability of ending the trial
during stage 1. However, if the ‘true’ response probability was 25%, then
there was a 12.67% probability that the trial would have been stopped in
stage 1. The alpha level was 0.04 and the power was 0.8.
Primary end point of the phase II part was objective RR according to
RECIST criteria. Secondary end points were toxicity according to NCI–CTC
v3.0, progression-free survival and overall survival.
The trial treatment was defined as worth of further investigation if
four or more objective responses were observed by the end of the phase II
part of the trial.
The study was conducted according to the ethical principles of the
Declaration of Helsinki and Good Clinical Practice and was approved by
health authorities and independent ethics committees for each participating
center. Trial monitoring was carried out by an independent external clinical
research organization (Pharma Brains AG, Basel, Switzerland).
The trial is registered on the USA NCI Web site www.ClinicalTrials.gov
(NCT00744640).
results
Forty-seven patients with histologically confirmed APC were
recruited from seven centers from November 2005 to
Dose level Oxaliplatin
(mg/m2 d1)
Capecitabine
(mg/m2 · 28 doses)
1 85 650
2 100 650
3 115 650
4 130 650
5 130 800
6 130 900
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September 2008. Two patients were excluded from the analysis:
One patient committed suicide after signing informed consent
but before performing any study-specific intervention, whereas
major violation of inclusion criteria (active life-threatening
concomitant disease: gastrointestinal bleeding, not tumor-
related) precluded trial participation of the second patient.
Baseline characteristics of all 45 patients are summarized in
Table 1.
dose escalation and DLT
Twenty patients were treated in the phase I part of this
study. While escalating oxaliplatin from 85 to 130 mg/m2,
the maximum tolerated dose was not reached.
However, when further escalating capecitabine in this
combination (to 800 mg/m2 twice daily) DLTs occurred in
two patients: grade 3 diarrhea requiring hospitalization and
grade 4 thrombocytopenia. The RD of this 3-week regimen
was therefore defined as oxaliplatin 130 mg/m2 d1,
capecitabine 650 mg/m2 b.i.d. d1–14 and gemcitabine 1000
mg/m2 d1, d8.
safety and toxicity
Two hundred and three cycles of chemotherapy were
administered to 45 patients. Grade 3/4 toxic effects are
summarized in Table 2. Predominant adverse effects were
neutropenia (33 patients; 30% of cycles), thrombocytopenia
(28 patients; 26% of cycles) and diarrhea (9 patients; 5%
of cycles).
Twenty-eight patients were treated at the RD with a total of
111 cycles. Frequency of grade 3/4 neutropenia,
thrombocytopenia and grade 3 diarrhea was similar in this
group occurring in 33%, 32% and 7% of cycles, respectively.
Also, in the group of 30 patients with good baseline
performance status (PS; 90%–100%), the percentage of cycles
(n = 141) with grade 3/4 neutropenia, thrombocytopenia and
grade 3 diarrhea was 32%, 30% and 5%, respectively.
One treatment-related death occurred in a 66-year-old man
who was treated at the RD and died of diffuse intestinal
bleeding from treatment-induced mucositis during the first
cycle of chemotherapy. In two other patients, who both died
after having completed three cycles of treatment, the relation
between death and treatment was uncertain: The first patient
died of tumor progression and gram-negative sepsis and the
second died of intractable diarrhea, which occurred 1 week
after active chemotherapy treatment had been stopped.
A median of six cycles (range 1–11) was administered per
patient. The reason for stopping treatment was disease
progression in 22 patients, completion of the planned six cycles
in 14 patients, adverse events in 7 patients and patient’s wish in
2 patients. In one patient, trial treatment was stopped after four
cycles because of an excellent tumor response allowing for
a switch in therapeutic strategy to curative surgery.
At the RD, dose reductions of at least one of the three
drugs—as prespecified in the protocol—were necessary in 56
(51%) of 111 cycles. For gemcitabine, capecitabine and
oxaliplatin, 83% (range 50%–100%), 75% (range 9%–100%)
and 91% (range 31%–100%), respectively, of the planned dose
were administered at the RD (mean relative dose intensity per
patient). Hematologic toxicity was the most common reason
for dose reductions (Table 2). Diarrhea led to a dose reduction
in 13 (12%), HFS in 3 (3%) and neurotoxicity in none of the
111 cycles at RD.
Figure 1 shows the percentage of patients who were treated
with the planned full dose of each drug in each successive cycle.
Table 1. Patient characteristics
Ntotal = 45
Median age, years (range) 63 (35–77)
n %
Sex
Female 21 47
Male 24 53
Karnofsky performance status
90%–100% 30 67
60%–80% 15 33
Extent of disease
Locally advanced 11 24
Metastatic 34 76
Histology
Well differentiated – –
Moderately differentiated 13 29
Poorly differentiated 7 16
Unknown 25 55
Prior surgery 9 20
Whipple procedure with
R0-resection
1 2
Explorative surgery with
biliodigestive anastomosis
and/or gastroenterostomy
8 18
Prior radiotherapy – –
Part of the study
Phase I (dose escalation) 20 44
Phase II (recommended dose) 25 56
Median baseline tumor marker CA
19-9 IU/ml (range)
1074 (<1–456 600)
Table 2. Treatment-related toxicity according to NCI–CTC v3.0
n = 203 cycles n = 45 patients
Grade 3 Grade 4 Grade 3 Grade 4
n % n % n % n %
Hematologic toxicity
Neutropenia 45 22 16 8 20 44 13 29
Febrile neutropenia – – 1 0.5 – – 1 2
Thrombocytopenia 40 20 12 6 18 40 10 22
Non-hematologic toxicity
Diarrhea 11 5 – – 9 20 – –
Infection 1 0.5 – – 1 2 – –
SIRS 1 0.5 – – 1 2 – –
Hand–foot syndrome 1 0.5 1 2
In addition, one treatment-related death occurred (grade 5 mucositis). For
two other fatal adverse events (infection and diarrhea), association with
treatment is uncertain (see text). No grade 3/4 paresthesia occurred.
NCI–CTC v3.0: National Cancer Institute—Common Toxicity Criteria
version 3.0; SIRS: systemic inflammatory response syndrome.
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Of the 22 patients who underwent all six cycles, full doses of
gemcitabine, capecitabine and oxaliplatin were given to 7, 6 and
9 patients, respectively.
After study treatment, 29 patients (64%) went on to a second
line and 11 patients (24%) on to a third line of systemic
treatment with various regimens including gemcitabine,
capecitabine, erlotinib and experimental drugs in clinical trials.
efficacy and survival
CT scans of all 41 patients with measurable disease—centrally
reviewed by an independent radiologist blinded to the clinical
history of the patients—showed a partial response according to
RECIST criteria in 17 patients (41%, 95% CI 26% to 56%). In
15 patients (37%, 95% CI 22% to 52%), imaging revealed stable
disease, whereas the remaining 9 patients (22%, 95% CI 9% to
35%) progressed while on treatment. Fourteen of the 17
patients with partial remissions started chemotherapy in a good
PS (KPS 90%–100%).
After a median follow-up of 27.2 months (95% CI 24.0–30.4
months), all 45 patients had experienced disease progression
and 41 patients (91%) had died. Median progression-free
survival time was 4.3 months (95% CI 3.3–5.4 months).
Patients lived for a median time of 7.8 months (95% CI 5.3–
10.3 months). Median survival time for the 30 patients with
good PS was 8.9 months (95% CI 5.7–12.0 months) (Figure 2).
discussion
Progress in medical treatment of patients with APC comes in
small steps. Out of an extensive body of clinical research data,
three classes of cytotoxic drugs emerged as effective and life
prolonging [4–6]. This is the first report of a chemotherapy
regimen combining all three drugs in a first-line regimen. The
RD of this 3-week regimen determined in the phase I part of
this study consists of oxaliplatin (Ox) 130 mg/m2 d1,
capecitabine (Cap) 650 mg/m2 b.i.d. d1–14 and gemcitabine
(Gem) 1000 mg/m2 d1, d8. This corresponds to full standard
therapeutic doses in APC. Objective RR assessed by central
radiological review, the primary end point of the phase II part
of this trial, was 41% (17 of 41 patients with measurable
disease; 95% CI 26% to 56%) and—by far—met the protocol-
defined precondition warranting further investigation of this
regimen.
No DLTs occurred when escalating oxaliplatin up to
130 mg/m2. Diarrhea and thrombocytopenia were dose
limiting, when Cap was escalated from 650 to 800 mg/m2
b.i.d. Interestingly, DLTs occurred at exactly the same dose
escalation step in the similarly designed phase I trial of the
GemCap doublet, where grade 4 neutropenia and
thrombocytopenia and mucositis were dose limiting as well
[12]. Taken aside a certain possibility of chance inherent to
the phase I design, this implies that the addition of a full dose
of Ox does not shift the limiting toxicity profile significantly,
at least not during the first two cycles.
Tan et al. [13] studied a combination regimen of the same
three drugs in 30 patients with advanced upper gastrointestinal
malignancies including 15 patients with pancreatic cancer. In
contrast to this study, the majority of patients were pretreated.
The 29-day regimen consisted of oxaliplatin 100 mg/m2 i.v. d1
and d15, gemcitabine 800 mg/m2 i.v. as fixed dose rate infusion
d1, d15 and capecitabine 800 mg/m2 b.i.d. d1–d7 and
d15–d21. Intriguingly, DLTs in their study included grade 3
fatigue and grade 3 dyspnea, none of which were dose limiting
with any of the single drugs involved.
In our trial, most adverse events, including neutropenia,
febrile neutropenia, HFS and peripheral polyneuropathy,
occurred at or below the frequency expected from the GemCap
[5, 7] and GemOx [10, 11] regimen in APC. However,
thrombocytopenia (grade 3/4 in 28 of 45 patients) and diarrhea
(grade 3 in 9 of 45 patients) were more common with the triple
combination and the main reasons for dose adjustments.
Thrombocytopenia was well manageable with dose reductions
and/or delays and no platelet transfusions were required. Grade
3/4 diarrhea, consistently reported in 5%–6% of patients
treated for APC [5, 7, 10, 11], represents a serious clinical
problem that needs careful monitoring when exposing these
patients to any chemotherapy. One patient died of acute
mucositis with diarrhea and intestinal bleeding during the first
treatment cycle. It is well known that dihydropyrimidine
dehydrogenase (DPD) deficiency, present in 3%–5% of the
population, renders some patients extremely prone to severe
fluoropyrimidine toxicity [14]. DPD status in this patient was
not known.
RR according to RECIST criteria, the primary efficacy end
point of the phase II study, was 41% (95% CI 26% to 56%) for
all patients and 50% (95% CI 31% to 69%) for patients with
good PS, hence much higher than expected from previous
studies using the doublet GemOx (10% to 27%) [10, 11] or
GemCap (15%–19%) [5, 7]. Therefore, this regimen—in
contrast to single-agent and doublet regimens—leads to
a relevant tumor volume reduction in a substantial percentage
of patients. In our series, a patient with primarily inoperable
locally advanced disease was rendered eligible for resection
following an excellent response to chemotherapy. The patient
underwent complete R0-resection after four cycles of
GEMOXEL and stayed disease free for 15 months.
In the majority of patients, however, response to
chemotherapy was short lived with a median time to
Figure 1. Percentage of patients treated at the full planned dose of each of
the three drugs gemcitabine, capecitabine and oxaliplatin.
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progression of 4.3 months (95% CI 3.3–5.4 months). This rapid
development of chemotherapy resistance—even after initial
susceptibility mirrored in the high RR—makes this regimen of
limited value in the palliative setting of metastatic disease,
where short-lived tumor volume reduction offers little clinical
benefit.
PS is a prognostic factor of paramount importance in APC
[6]. The decision to include patients with a relatively poor PS of
60%–80%, who, in general, are more susceptible to adverse
events, might limit the ability of this trial to truly describe
toxicity—and efficacy—of this triple combination for patients
with good PS. Therefore, future studies of this combination
regimen should focus on patients with good PS.
In summary, combining gemcitabine, oxaliplatin and
capecitabine, three active cytotoxic drugs in APC, as a first-line
regimen is feasible and the triplet clearly meets the prespecified
efficacy parameters. Given the high percentage of patients
experiencing significant tumor volume reductions—a
parameter most relevant in the preoperative setting—further
investigation of this regimen in patients with locally advanced
disease in the neoadjuvant setting is warranted.
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